Ionis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical ...

FDA approved zilganersen as the first disease-modifying therapy for Alexander disease, an ultra-rare, progressive ...

In a conversation with Pharmaceutical Executive, Nate Hill, Co-Founder & CEO of Strive Pharmacy, discussed the regulatory ...

When treating IBD, what are the restraints with JAK inhibitors? Christian Thienel: JAK inhibitors have been around for quite a while, and they are understood to be highly effective. The JAK-STAT ...

It has been an eventful weeks in pharma and biotech news so far in 2026. Here is a guide to every major story and what it ...

Ultragenyx shares plunge after apazunersen fails its Phase III trial in Angelman syndrome, Mark Cziraky of Carelon Research ...

Ultragenyx is reviewing program disposition and implementing significant expense reductions as brokerages cut price targets ...

Nate Hill, co-founder & CEO, Strive, notes the key milestone to watch for during the remaining step in FDA's formal Category ...

Recently, Pharmaceutical Executive spoke with Christian Thienel, director at Back Bay Life Sciences, about the ongoing issues ...

Pharmaceutical Executive recently spoke with Mark Cziraky, president of Carelon Research. The company just signed a deal with ...

The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA ...

Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...